Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01908777 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma
A Phase 2 study of T Cell Non-Hodgkin Lymphoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 47
- Enrollment target
- 10
- Study locations
NCT01908777: Completed Phase 2 study of T Cell Non-Hodgkin Lymphoma, sponsored by Memorial Sloan Kettering Cancer Center.
NCT01908777 is a Phase 2 study of T Cell Non-Hodgkin Lymphoma that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 47 participants, above the 41-participant average among 5 other T Cell Non-Hodgkin Lymphoma trials with a reported enrollment target (15% higher). The trial reports 10 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01908777, a Phase 2 study of T Cell Non-Hodgkin Lymphoma, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 47 participants
- Enrollment target
- 10
- Study locations
Study Summary
The purpose of this study is to test the benefit of a chemotherapy drug called romidepsin in patients with T Cell Non-Hodgkin Lymphoma (T NHL) who have undergone autologous transplantation.
Conditions Studied
Interventions
- OTHER High Dose Chemotherapy with Autologous Stem Cell Transplant Followed by Maintenance Therapy with Romidepsin
Study Locations (10)
New York
- Memorial Sloan Kettering Cancer Center @ Suffolk - Commack
- Memorial Sloan Kettering Westchester - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- Weill Cornell Medical Center - New York
- Memorial Sloan Kettering Nassau - Uniondale
New Jersey
- Memorial Sloan Kettering Cancer Center - Basking Ridge
- Memorial Sloan Kettering Monmouth - Middletown
Washington
- Fred Hutchinson Cancer Research Center (Data Collection Only) - Seattle
- University of Washington (Data Collection Only) - Seattle
Florida
- Moffitt Cancer Center - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2013-07-16 |
| Est. Completion | 2025-10-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01908777
The ClinicalTrials.gov registry entry for NCT01908777 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 41-participant average among 5 other T Cell Non-Hodgkin Lymphoma trials with a reported enrollment target (15% higher). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with T Cell Non-Hodgkin Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which High Dose Chemotherapy with Autologous Stem Cell Transplant Followed by Maintenance Therapy with Romidepsin is the first listed.
NCT01908777 reports 10 study locations spanning 4 distinct geographic areas - top geographies include New York, New Jersey, Washington.
Frequently Asked Questions
What is clinical trial NCT01908777 about?
NCT01908777 is a clinical study titled "A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma". The purpose of this study is to test the benefit of a chemotherapy drug called romidepsin in patients with T Cell Non-Hodgkin Lymphoma (T NHL) who have undergone autologous transplantation.
What is the current status of trial NCT01908777?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 47 participants. The study started on 2013-07-16. Estimated completion is 2025-10-03.
What conditions does trial NCT01908777 study?
This clinical trial studies the following conditions: T Cell Non-Hodgkin Lymphoma.
What interventions are being tested in trial NCT01908777?
The interventions under investigation include: High Dose Chemotherapy with Autologous Stem Cell Transplant Followed by Maintenance Therapy with Romidepsin (OTHER).
Who is sponsoring clinical trial NCT01908777?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01908777 being conducted?
This trial has 10 study locations across Florida, New Jersey, New York, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for T Cell Non-Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma
COMPLETED · Phase 2
-
CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL)
RECRUITING · Phase 1
-
Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies
ACTIVE NOT RECRUITING · Phase 1
-
Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant
COMPLETED · Phase 1
-
A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)
COMPLETED · Phase 1
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.